Molecular mechanisms underlying the enhanced efficacy of inhaled corticosteroid/long-acting beta2-adrenoceptor agonist combinations used in asthma

吸入皮质类固醇/长效β2-肾上腺素受体激动剂组合增强哮喘疗效的分子机制

• 批准号: 366550
• 负责人: Newton Robert
• 金额: $ 7.29万
• 依托单位: University of Calgary
• 依托单位国家: 加拿大
• 项目类别: Operating Grants
• 财政年份: 2016
• 资助国家: 加拿大
• 起止时间: 2016-11-01 至 2017-11-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=366550&lang=en
• 关键词: Gene Expression; Glucocorticoids / Corticosteroids; Long-Acting Beta2-Agonists; Regulation; Transcriptional Control

Asthma is a chronic inflammatory disease, characterised by intermittent airways constriction and occurs in up to 10% of individuals. Regular inhaled glucocorticoids (GCs) are clinically referred to as inhaled corticosteroid (ICS) and dampen lung inflammat

哮喘是一种慢性炎症性疾病，其特征是间歇性气道收缩，发生在高达10%的个体中。常规吸入性糖皮质激素（GC）在临床上称为吸入性皮质类固醇（ICS），可抑制肺部炎症，